Latest news
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 05:47:00 GMTAbbVie prices $9.9B senior notes to fund acquisition - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 22:26:00 GMTThis Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 01:20:00 GMTAbbvie (ABBV) PT Raised to $288 at Guggenheim - StreetInsiderStreetInsider · Tue, 04 Aug 2026 10:49:00 GMTAbbVie Targets Obesity Market With New Phase 2 ABBV-295 Trial - The Globe and MailThe Globe and Mail · Tue, 04 Aug 2026 07:00:00 GMTAbbVie (ABBV) Q2 2026 Earnings Call Transcript - The Globe and MailThe Globe and Mail · Tue, 04 Aug 2026 00:09:00 GMTAbbVie Quietly Solved Its Biggest Problem—Now What? - The Globe and MailThe Globe and Mail · Sun, 02 Aug 2026 15:00:00 GMTAbbVie Earnings Call: Growth Engines Outpace Legacy Drag - The Globe and MailThe Globe and Mail · Sun, 02 Aug 2026 00:18:00 GMT